Migräne ade? - 500 Beiträge pro Seite
eröffnet am 30.10.05 15:36:16 von
neuester Beitrag 16.02.06 20:34:09 von
neuester Beitrag 16.02.06 20:34:09 von
Beiträge: 13
ID: 1.016.482
ID: 1.016.482
Aufrufe heute: 0
Gesamt: 685
Gesamt: 685
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| gestern 11:52 | 2141 | |
| vor 52 Minuten | 2060 | |
| gestern 22:26 | 1282 | |
| 08.05.24, 11:56 | 1278 | |
| vor 1 Stunde | 1121 | |
| vor 38 Minuten | 1087 | |
| vor 1 Stunde | 960 | |
| vor 55 Minuten | 886 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.772,85 | +0,46 | 131 | |||
| 2. | 3. | 0,2170 | +3,33 | 125 | |||
| 3. | Neu! | 8,2570 | +96,67 | 108 | |||
| 4. | 4. | 156,46 | -2,31 | 103 | |||
| 5. | 14. | 5,7540 | -2,18 | 56 | |||
| 6. | 2. | 0,2980 | -3,87 | 50 | |||
| 7. | 5. | 2,3720 | -7,54 | 49 | |||
| 8. | 7. | 6,8000 | +2,38 | 38 |
Feedback
NMT Medical(NMTI)ist auf dem besten Weg Migräne Patienten
neue Hoffnung zu geben.
Analysten-Empfehlung : http://aktien.onvista.de/empfehlungen.html?ID_OSI=90437#news
neue Hoffnung zu geben.
Analysten-Empfehlung : http://aktien.onvista.de/empfehlungen.html?ID_OSI=90437#news
Aktuell
Aktueller Durchschnitt von insgesamt 1 Analysten
Sell Underperform Hold Buy ...Strong Buy
Änderungen
Aktueller Durchschnitt von insgesamt 1 Analysten
Sell Underperform Hold Buy ...Strong Buy
Änderungen
Interessanter Bericht : http://www.prnewswire.co.uk/cgi/news/release?id=146754
Hallo,
du hast BM
du hast BM
Trading Spotlight
Unglaublichdiese Woche schon wiederum 2 Dollar gestiegen
Das könnte der Grund sein
http://www.iht.com/articles/2005/11/10/business/heart.php
Die Party geht weiter
Aktueller Kurs USD 16.50
Wenn es so weiter geht sind wir Ende November bei USD 20
Aktueller Kurs USD 16.50Wenn es so weiter geht sind wir Ende November bei USD 20
GREAT NEWS ZU ERSTEN 
BOSTON, Nov. 29 /PRNewswire-FirstCall/ -- NMT Medical, Inc. announced today that the Company has completed patient enrollment in its BEST study (BioSTAR(TM) Evaluation STudy) in the United Kingdom. The multi-center study, which received regulatory approval in June 2005, is evaluating the Company`s new bioabsorbable collagen matrix technology designed to promote biological closure of structural heart defects such as PFO (patent foramen ovale). The BioSTAR(TM) implant is delivered through a minimally invasive, catheter-based procedure.
Michael Mullen, M.D., Interventional Cardiologist at Royal Brompton Hospital, London and Chief Investigator for the BEST study in the United Kingdom, said, "Based on our initial implant experience, we are very excited by the performance of this new technology. What is remarkable about BioSTAR(TM) is that once implanted, it seems to "melt" onto the septal wall with little or no profile. We are seeing higher acute closure rates with this implant technology compared to what is currently available. I believe the concept of bioabsorbable devices for closing PFOs may now be a reality and represents a major milestone in patient management."
Approximately 60 patients were enrolled in the BEST study and will be followed for six months. The study was designed to gain European commercial approval for BioSTAR(TM) through the CE Mark process. Approval is currently expected by year end 2006.
John E. Ahern, NMT`s President and Chief Executive Officer, said, "Completing patient enrollment in our BEST study earlier than originally anticipated is an important event for the Company and for our clinical researchers seeking better ways to treat their patients with the PFO defect. The early data on BioSTAR(TM) is encouraging and confirms what was observed in our extensive preclinical research."
BioSTAR(TM) combines an advanced biomaterial and NMT`s proven STARFlex(R) delivery platform. Once implanted, BioSTAR(TM) creates a bioscaffold that promotes native tissue deposition. During that biological closure process, the collagen matrix dissolves leaving behind natural tissue that completely covers the STARFlex(R) alloy framework. The bioabsorbable collagen matrix used in BioSTAR(TM) also has the potential to deliver and localize drugs, genes, cells and other materials that may further enhance PFO closure outcomes. The BioSTAR(TM) implant being evaluated in the BEST clinical study incorporates an ionically bound heparin substrate that elutes over time. This feature is designed to minimize device thrombus, a potential risk with all current intra-cardiac devices.
Ahern concluded, "As the only company with five PFO-related trials underway, NMT Medical is committed to maintaining its technology and clinical research leadership position in the emerging PFO closure opportunity. BioSTAR(TM) and the BEST study, combined with our ongoing PFO/migraine and PFO/stroke trials, are an important part of our leadership strategy. As previously announced, we currently expect to commence enrollment in our pivotal PFO/migraine clinical study in the U.S., MIST II, in the first quarter of 2006. In addition, we currently expect the final results of MIST, our PFO/migraine study conducted in the United Kingdom, to be available in late March or early April 2006. We remain positive about the progress we are making and the milestones the Company achieved in 2005."
BOSTON, Nov. 29 /PRNewswire-FirstCall/ -- NMT Medical, Inc. announced today that the Company has completed patient enrollment in its BEST study (BioSTAR(TM) Evaluation STudy) in the United Kingdom. The multi-center study, which received regulatory approval in June 2005, is evaluating the Company`s new bioabsorbable collagen matrix technology designed to promote biological closure of structural heart defects such as PFO (patent foramen ovale). The BioSTAR(TM) implant is delivered through a minimally invasive, catheter-based procedure.
Michael Mullen, M.D., Interventional Cardiologist at Royal Brompton Hospital, London and Chief Investigator for the BEST study in the United Kingdom, said, "Based on our initial implant experience, we are very excited by the performance of this new technology. What is remarkable about BioSTAR(TM) is that once implanted, it seems to "melt" onto the septal wall with little or no profile. We are seeing higher acute closure rates with this implant technology compared to what is currently available. I believe the concept of bioabsorbable devices for closing PFOs may now be a reality and represents a major milestone in patient management."
Approximately 60 patients were enrolled in the BEST study and will be followed for six months. The study was designed to gain European commercial approval for BioSTAR(TM) through the CE Mark process. Approval is currently expected by year end 2006.
John E. Ahern, NMT`s President and Chief Executive Officer, said, "Completing patient enrollment in our BEST study earlier than originally anticipated is an important event for the Company and for our clinical researchers seeking better ways to treat their patients with the PFO defect. The early data on BioSTAR(TM) is encouraging and confirms what was observed in our extensive preclinical research."
BioSTAR(TM) combines an advanced biomaterial and NMT`s proven STARFlex(R) delivery platform. Once implanted, BioSTAR(TM) creates a bioscaffold that promotes native tissue deposition. During that biological closure process, the collagen matrix dissolves leaving behind natural tissue that completely covers the STARFlex(R) alloy framework. The bioabsorbable collagen matrix used in BioSTAR(TM) also has the potential to deliver and localize drugs, genes, cells and other materials that may further enhance PFO closure outcomes. The BioSTAR(TM) implant being evaluated in the BEST clinical study incorporates an ionically bound heparin substrate that elutes over time. This feature is designed to minimize device thrombus, a potential risk with all current intra-cardiac devices.
Ahern concluded, "As the only company with five PFO-related trials underway, NMT Medical is committed to maintaining its technology and clinical research leadership position in the emerging PFO closure opportunity. BioSTAR(TM) and the BEST study, combined with our ongoing PFO/migraine and PFO/stroke trials, are an important part of our leadership strategy. As previously announced, we currently expect to commence enrollment in our pivotal PFO/migraine clinical study in the U.S., MIST II, in the first quarter of 2006. In addition, we currently expect the final results of MIST, our PFO/migraine study conducted in the United Kingdom, to be available in late March or early April 2006. We remain positive about the progress we are making and the milestones the Company achieved in 2005."
GREAT NEWS ZUM ZWEITEN
Rodman & Renshaw, LLC Initiates Coverage of NMT Medical, Inc. With A Market Outperform Rating
Analyst Sets 12 Month Target Price of $26.00
Rodman & Renshaw, LLC Initiates Coverage of NMT Medical, Inc. With A Market Outperform Rating
Analyst Sets 12 Month Target Price of $26.00
Wir sind über USD 19
Die neue Woche fängt schon gut an!!RT USD 20.10
Neues ATH USD 20.85
Seit meiner Erstempfehlung vom 30.10.05 sind wir mit über
120% im Plus Aktuell RT USD 24.50 !!Ende März anfangs
April kommen dann Die Resultate der MIST II Studie in England.Fallen die gut aus explodiert der Kurs
120% im Plus
Aktuell RT USD 24.50 !!Ende März anfangsApril kommen dann Die Resultate der MIST II Studie in England.Fallen die gut aus explodiert der Kurs
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 78 | ||
| 42 | ||
| 22 | ||
| 19 | ||
| 19 | ||
| 17 | ||
| 15 | ||
| 12 | ||
| 11 | ||
| 10 |
| Wertpapier | Beiträge | |
|---|---|---|
| 9 | ||
| 8 | ||
| 7 | ||
| 7 | ||
| 7 | ||
| 6 | ||
| 6 | ||
| 6 | ||
| 6 | ||
| 5 |
